



NOTICE TO LOUISIANA 340B COVERED ENTITIES
REGARDING UPDATES TO TEVA PHARMACEUTICALS USA, INC
340B PROGRAM INTEGRITY INITIATIVE

July 31, 2023

Dear Louisiana Covered Entity Customer,

On June 19, 2023, Louisiana signed HB 548 into law that will become effective August 1, 2023. To ensure compliance with the 340B Program requirements under Louisiana HB 548, Teva Pharmaceuticals USA, Inc. is voluntarily implementing the changes described below to its 340B Program Integrity Initiative that became effective July 5, 2023.

Effective August 1, 2023:

- Louisiana covered entities originally subject to Teva's 340B Program Integrity Initiative will no longer be limited to a single contract pharmacy location for shipment / delivery of 340B-discounted Teva products. Louisiana covered entities will be able to place Bill To / Ship To replenishment orders through an unlimited number of contract pharmacies.
- While Teva will no longer require the submission of 340B claims data for Louisiana covered entities, we strongly encourage all 340B covered entities to voluntarily continue to submit 340B claims data through the 340B ESP platform for all utilization dispensed through in-house and contract pharmacies. This will support Teva's ongoing efforts to maintain 340B Program integrity and transparency.

Teva will continue to monitor and evaluate the increase in duplicate discounts and diversion of 340B purchased medicines that has accompanied the growth in contract pharmacy arrangements. To support Teva's continued commitment to uphold the integrity of the 340B program, we may at our own discretion, place additional conditions or revert to original policy requirements.

If you have questions regarding the changes to our 340B Program described in this letter, please contact support@340Besp.com.

Thank you.